These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26296970)

  • 21. Catumaxomab: clinical development and future directions.
    Linke R; Klein A; Seimetz D
    MAbs; 2010; 2(2):129-36. PubMed ID: 20190561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.
    Pietzner K; Vergote I; Santoro A; Chekerov R; Marmé F; Rosenberg P; Martinius H; Friccius-Quecke H; Sehouli J
    Med Oncol; 2014 Dec; 31(12):308. PubMed ID: 25367854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
    Berek JS; Edwards RP; Parker LP; DeMars LR; Herzog TJ; Lentz SS; Morris RT; Akerley WL; Holloway RW; Method MW; Plaxe SC; Walker JL; Friccius-Quecke H; Krasner CN
    Int J Gynecol Cancer; 2014 Nov; 24(9):1583-9. PubMed ID: 25254563
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
    Ströhlein MA; Heiss MM
    Future Oncol; 2010 Sep; 6(9):1387-94. PubMed ID: 20919824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.
    Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H
    Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.
    Sehouli J; Pietzner K; Wimberger P; Vergote I; Rosenberg P; Schneeweiss A; Bokemeyer C; Salat C; Scambia G; Berton-Rigaud D; Santoro A; Cervantes A; Trédan O; Tournigand C; Colombo N; Dudnichenko AS; Westermann A; Friccius-Quecke H; Lordick F
    Med Oncol; 2014 Aug; 31(8):76. PubMed ID: 24965536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
    Patriarca C; Macchi RM; Marschner AK; Mellstedt H
    Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of catumaxomab in the treatment of malignant ascites.
    Sebastian M
    Cancer Manag Res; 2010 Nov; 2():283-6. PubMed ID: 21188120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Catumaxomab: a bispecific trifunctional antibody.
    Sebastian M; Kuemmel A; Schmidt M; Schmittel A
    Drugs Today (Barc); 2009 Aug; 45(8):589-97. PubMed ID: 19927225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
    Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer.
    Papanikolaou G; Fotopoulou C; Braicu I; Chekerov R; Schmidt SC; Pietzner K; Sehouli J
    Anticancer Res; 2011 Aug; 31(8):2603-8. PubMed ID: 21778311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy.
    Ströhlein MA; Lefering R; Bulian DR; Heiss MM
    Med Hypotheses; 2014 Mar; 82(3):295-9. PubMed ID: 24411128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single nucleotide polymorphisms of the EpCAM-coding gene TACSTD1 in patients with ovarian cancer and their potential translational aspects.
    Heubner M; Wimberger P; Kasimir-Bauer S; Singer BB; Ruf P; Kimmig R; Siffert W
    Arch Gynecol Obstet; 2015 Dec; 292(6):1367-72. PubMed ID: 26115884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.
    Pilanc KN; Ordu Ç; Akpnar H; Balc C; Başsülü N; Köksal Üİ; Elbüken F; Okutur K; Bülbül G; Sağlam S; Demir G
    Am J Ther; 2016; 23(4):e1078-81. PubMed ID: 24732906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
    Sebastian M; Kiewe P; Schuette W; Brust D; Peschel C; Schneller F; Rühle KH; Nilius G; Ewert R; Lodziewski S; Passlick B; Sienel W; Wiewrodt R; Jäger M; Lindhofer H; Friccius-Quecke H; Schmittel A
    J Immunother; 2009; 32(2):195-202. PubMed ID: 19238019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.
    Hirschhaeuser F; Walenta S; Mueller-Klieser W
    Cancer Immunol Immunother; 2010 Nov; 59(11):1675-84. PubMed ID: 20652245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study.
    Li YN; Li YY; Wang SX; Ma XY
    Curr Med Sci; 2023 Jun; 43(3):539-550. PubMed ID: 37119369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
    Jiang S; Pei L; Yang ZL; Liu G
    Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.
    Atanackovic D; Reinhard H; Meyer S; Spöck S; Grob T; Luetkens T; Yousef S; Cao Y; Hildebrandt Y; Templin J; Bartels K; Lajmi N; Stoiber H; Kröger N; Atz J; Seimetz D; Izbicki JR; Bokemeyer C
    Hum Vaccin Immunother; 2013 Dec; 9(12):2533-42. PubMed ID: 23955093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.